glp-1 agonists marketing strategies 2025 Weight Loss Drugs Market Report, 2025-2030 GLP-1 Analogues Market Size, Share

[DOI] [PMC free article] [PubMed] [Google Scholar] 134.Branca D., Roberti M.S., Vincenti E., Scutari G

This is particularly relevant in muscle and cardiovascular research models

Narcolepsy: Low acylcarnitine levels are found in patients with narcolepsy, a sleep disorder that causes daytime drowsiness as well as a sudden loss of muscle tone (cataplexy)

Some studies have found that about half of people who start taking a GLP-1 drug for weight loss stop taking it within a yearfor various reasonsand many people think they can stop taking anti-obesity drugs once theyve reached a desired weight, Oczypok and Anderson write

Hows your diabetes control